Nadia, India

Pranab Chatterjee

This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Ranbaxy Laboratories, Inc.. Active years: 2014.

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Pranab Chatterjee: Innovator in Pharmaceutical Chemistry

Introduction

Pranab Chatterjee is a notable inventor based in Nadia, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative processes for drug preparation. His work has implications for the efficiency and effectiveness of pharmaceutical manufacturing.

Latest Patents

Pranab Chatterjee holds a patent for a process titled "Process for the preparation of febuxostat." This patent describes an improved and efficient method for synthesizing 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid (febuxostat) that is substantially free from amide by-products. This innovation enhances the production quality and reduces waste in the pharmaceutical industry.

Career Highlights

Chatterjee is currently employed at Ranbaxy Laboratories, Inc., where he applies his expertise in pharmaceutical development. His work at this prominent company has allowed him to contribute to various projects aimed at improving drug formulations and processes.

Collaborations

Throughout his career, Pranab has collaborated with several talented individuals, including Asok Nath and Sarbjot Singh Sokhi. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.

Conclusion

Pranab Chatterjee's contributions to pharmaceutical chemistry, particularly through his patent on febuxostat, highlight his role as an innovator in the industry. His work continues to influence the field and improve drug manufacturing processes.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…